Application of chenodeoxycholic acid in preparation of medicine for preventing and / or treating acute pancreatitis

By using gossipal deoxycholic acid, the problem of pancreatic necrosis in acute pancreatitis is provided with new preventive and therapeutic measures, significantly improving acute pancreatitis and severe acute pancreatitis by reducing acinar cell death and improving seroenzyme indicators. the occurrence and development.

CN119055660APending Publication Date: 2024-12-03YANGZHOU FIRST PEOPLES HOSPITAL +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310634972.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-05-31
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

There is a lack of effective prevention and treatment measures in acute pancreatitis, especially for pancreatic necrosis, resulting in high mortality and organ failure.

Method used

Genuine deoxycholic acid is used as a drug, and through gavage or intraperitoneal injection, it reduces acinar cell death induced by cholecystotin and sodium taurocholate, reduces mitochondrial reactive oxygen level, and improves pancreatic tissue damage and seroenzymatic indicators.

Benefits of technology

It significantly improves the occurrence and development of acute pancreatitis and severe acute pancreatitis, reduces acinar cell mortality, improves pancreatic tissue damage and seroenzymatic indicators, and provides new drug applications for preventing and treating acute pancreatitis.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119055660A_ABST
    Figure CN119055660A_ABST
Patent Text Reader

Abstract

The invention discloses application of chenodeoxycholic acid in preparation of a medicine for preventing and / or treating acute pancreatitis, and belongs to the technical field of biological medicines. The invention discloses the new pharmaceutical application of chenodeoxycholic acid on acute pancreatitis or severe acute pancreatitis for the first time. By simulating two clinically related acute pancreatitis models, namely, a raulein-induced mouse acute pancreatitis model and a pancreatic duct retrograde injection sodium taurocholate-induced mouse severe acute pancreatitis model, through experimental verification, the chenodeoxycholic acid CDCA is subjected to intragastric administration or intraperitoneal injection to obtain the acute pancreatitis model. The occurrence and development of acute pancreatitis or severe acute pancreatitis related to the two models can be obviously improved, so that chenodeoxycholic acid can be expected to be applied to clinical prevention / treatment of AP.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of biomedicine, and specifically relates to the application of chenodeoxycholic acid in preparing a medicine for preventing and / or treating acute pancreatitis. Background Art

[0002] Acute pancreatitis (AP) is an acute inflammatory and damaging disease caused by the activation of pancreatic enzymes in the pancreas due to various etiologies, which leads to autodigestion, edema, and necrosis of pancreatic tissue. In about 15%-20% of AP patients, the inflammatory response is not limited to the pancreas itself, but may be followed by systemic inflammatory response, involving other distant organs, and progressing to severe acute pancreatitis, with a mortality rate of up to 40%-70%. Acinar cell damage / necrosis is the initiating factor of AP. Acinar cell necrosis (pancreatic necrosis) is closely related to the prognosis of AP. AP patients with pancreatic necrosis have significantly increased incidences of organ failure, systemic inflammatory response syndrome, etc., and patient mortality. To date, there is still a lack of targeted and effective prevention and treatment measures for pancreatic necrosis.

[0003] Bile acids are products of cholesterol metabolism. In addition to participating in the digestion and absorption of fat, they also have a variety of biological functions. In the human body, bile acid synthesis is mostly synthesized in the liver through the classical pathway with cholesterol as a substrate, catalyzed by cholesterol 7α-hydroxylase (cytochrome P450 7α-hydroxylase A1, CYP7A1) of the rate-limiting enzyme cytochrome P450 family. According to the source, bile acids can be divided into primary bile acids and secondary bile acids. Bile acids generated by cholesterol in hepatocytes under the catalysis of various enzymes are called primary bile acids, including cholic acid (CA) and chenodeoxycholic acid (CDCA). Secondary bile acids are converted by the catalysis of intestinal bacterial enzymes and the removal of hydroxyl groups after primary bile acids enter the intestine with bile. Clinical retrospective studies have found that serum total bile acid (TBA) is elevated in some AP patients (including non-biliary AP patients). The pancreatic necrosis rate, organ failure incidence and mortality rate of patients with high bile acid were higher than those of patients with normal bile acid. Multiple regression analysis showed that high bile acid was an independent risk factor for AP combined with organ failure. The study suggests that bile acid metabolism is closely related to pancreatic necrosis and organ failure, and may play a key regulatory role in the development of AP.

[0004] In recent years, it has been found that bile acids can act as signaling molecules dependent on receptors, regulating a variety of downstream pathological and physiological processes such as metabolism, inflammation, and immunity. Guo et al. found that bile acids can reduce the severity of many inflammatory diseases, such as the LPS-induced sepsis model. By inhibiting the production of inflammatory mediators by macrophages, the secondary metabolites of bile acids (such as deoxycholic acid) have significant anti-inflammatory effects. Experiments have confirmed that supplementation with taurodeoxycholic acid (TUDCA) and ursodeoxycholic acid (UDCA) has shown protective effects in various neurodegenerative animal models. Farnesoid X receptor (FXR) and cell surface G protein-coupled bile acid receptor (Takeda G-protein coupled receptor clone 5, TGR5) are two bile acid-specific receptors that have been studied more. FXR is mainly highly expressed in the liver and gastrointestinal tract and can be bound by downstream bile acids, among which CDCA has the strongest binding affinity. FXR agonists regulate the inflammatory response of bone marrow immune cells to alleviate multiple sclerosis and experimental autoimmune encephalomyelitis in mice.

[0005] However, the function of chenodeoxycholic acid (CDCA) in AP is still unknown, and there are no reports on the preventive and therapeutic effects of chenodeoxycholic acid (CDCA) in acute pancreatitis. Summary of the invention

[0006] The purpose of the present invention is to provide the use of chenodeoxycholic acid in preparing a medicine for preventing and / or treating acute pancreatitis.

[0007] In order to achieve the above object, the present invention adopts the following technical solutions:

[0008] The invention discloses for the first time the application of chenodeoxycholic acid in preparing medicine for preventing and / or treating acute pancreatitis.

[0009] Preferably, the drug is a drug for improving pancreatic tissue damage.

[0010] Further preferably, the pancreatic tissue damage includes edema, inflammatory exudate and acinar cell necrosis.

[0011] More preferably, the drug is a drug that reduces cholecystokinin-induced acinar cell death by chenodeoxycholic acid.

[0012] More preferably, the drug is a drug that reduces the level of mitochondrial reactive oxygen species in acinar cells induced by cholecystokinin through chenodeoxycholic acid.

[0013] More preferably, the drug is a drug that reduces sodium taurocholate-induced acinar cell death through chenodeoxycholic acid.

[0014] Preferably, the drug is a drug that improves serum enzymology and serum amylase levels.

[0015] Preferably, the drug is administered by intragastric or intraperitoneal injection.

[0016] The invention also discloses the use of chenodeoxycholic acid in preparing medicine for preventing and / or treating severe acute pancreatitis.

[0017] The invention also discloses a medicine for preventing and / or treating pancreatitis, acute pancreatitis or severe acute pancreatitis, which is prepared by adding chenodeoxycholic acid with or without adding pharmaceutically acceptable excipients.

[0018] Compared with the prior art, the present invention has the following beneficial effects:

[0019] The present invention discloses for the first time a new pharmaceutical use of chenodeoxycholic acid for acute pancreatitis or severe acute pancreatitis. The present invention simulates two clinically relevant acute pancreatitis models, namely, the mouse acute pancreatitis model induced by caerulein and the mouse severe acute pancreatitis model induced by retrograde injection of sodium taurocholate into the pancreatic duct, and experimentally verifies that administration of chenodeoxycholic acid (CDCA) by oral gavage or intraperitoneal injection can significantly improve the occurrence and development of acute pancreatitis or severe acute pancreatitis involved in the above two models, thus indicating that chenodeoxycholic acid can be expected to be used in the clinical prevention / treatment of AP.

[0020] Furthermore, the present invention verifies through experiments that chenodeoxycholic acid (CDCA) alleviates AP symptoms by improving pancreatic tissue damage, as well as serum enzymology and serum amylase levels.

[0021] Furthermore, the present invention has verified through experiments that both oral administration and intraperitoneal injection can effectively improve or alleviate the occurrence and development of acute pancreatitis.

[0022] Furthermore, the present invention clarifies the dosage for experimental mice by oral administration and intraperitoneal injection, and the optimal dosage is 40 mg / kg. BRIEF DESCRIPTION OF THE DRAWINGS

[0023] Figure 1 The figures show that intraperitoneal injection of different concentrations of chenodeoxycholic acid (CDCA) can significantly improve pancreatic damage (edema, inflammatory exudation, necrosis) in mice with acute pancreatitis induced by caerulein in Example 1; wherein, A is a pathological picture of HE staining of pancreatic tissue in mice; and B is a statistical picture of pancreatic damage pathological score.

[0024] Figure 2This is a graph showing the results of Example 1, in which intraperitoneal injection of different concentrations of chenodeoxycholic acid (CDCA) can reduce serum amylase and serum lipase levels in mice with acute pancreatitis induced by caerulein; wherein A is the serum amylase level; and B is the serum lipase level.

[0025] Figure 3 The optimal dose of intraperitoneal injection of chenodeoxycholic acid (CDCA) in Example 2 can significantly improve pancreatic injury (edema, inflammatory exudation, necrosis) in mice with severe acute pancreatitis induced by retrograde injection of sodium taurocholate; wherein A is a pathological image of HE staining of pancreatic tissue in mice; B is a statistical graph of pancreatic injury pathological score.

[0026] Figure 4 This is the result graph showing that intraperitoneal injection of the optimal dose of chenodeoxycholic acid (CDCA) in Example 2 can reduce serum amylase and serum lipase levels in mice with severe acute pancreatitis induced by retrograde injection of sodium taurocholate; wherein A is the serum amylase level; B is the serum lipase level.

[0027] Figure 5 The results of intragastric administration of the optimal dose of chenodeoxycholic acid (CDCA) in Example 3 can significantly improve pancreatic damage (edema, inflammatory exudation, necrosis) in mice with acute pancreatitis induced by caerulein; wherein A is a pathological image of HE staining of pancreatic tissue in mice; B is a statistical graph of pancreatic damage pathological score.

[0028] Figure 6 This is the result graph showing that oral administration of the optimal dose of chenodeoxycholic acid (CDCA) in Example 3 can reduce the levels of serum amylase and serum lipase in mice with acute pancreatitis induced by caerulein; wherein A is the serum amylase level; B is the serum lipase level.

[0029] Figure 7 This is a graph showing the results of Example 4 showing that different concentrations of chenodeoxycholic acid (CDCA) can reduce the level of LDH release in acinar cell damage induced by cholecystokinin (CCK) in vitro.

[0030] Figure 8 The results of PI fluorescence staining in Example 4 show that the optimal dose of chenodeoxycholic acid (CDCA) can reduce in vitro acinar cell necrosis. A is a PI staining fluorescence image of acinar cell injury model induced by CCK treated with CDCA; B is a fluorescence quantitative image.

[0031] Fig. 9 This is the result of JC-1 fluorescence staining showing that the optimal dose of chenodeoxycholic acid (CDCA) in Example 5 can reduce the mitochondrial membrane potential of acinar cells in vitro.

[0032] Fig.10This is the result of fluorescence staining showing that the optimal dose of chenodeoxycholic acid (CDCA) in Example 5 can reduce the MitoROS reactive oxygen species in mitochondria of acinar cells in vitro.

[0033] Fig.11 This is the result graph showing that the optimal dose of chenodeoxycholic acid (CDCA) in Example 6 can reduce the level of LDH release in acinar cell damage induced by sodium taurocholate (TLCS) in vitro. DETAILED DESCRIPTION

[0034] In order to enable those skilled in the art to better understand the scheme of the present invention, the technical scheme in the embodiments of the present invention will be clearly and completely described below in conjunction with the drawings in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work should fall within the scope of protection of the present invention.

[0035] It should be noted that the terms "first", "second", etc. in the specification and claims of the present invention and the above-mentioned drawings are used to distinguish similar objects, and are not necessarily used to describe a specific order or sequence. It should be understood that the data used in this way can be interchanged where appropriate, so that the embodiments of the present invention described herein can be implemented in an order other than those illustrated or described herein. In addition, the terms "including" and "having" and any variations thereof are intended to cover non-exclusive inclusions, for example, a process, method, system, product or device that includes a series of steps or units is not necessarily limited to those steps or units that are clearly listed, but may include other steps or units that are not clearly listed or inherent to these processes, methods, products or devices.

[0036] The present invention is further described in detail below in conjunction with the accompanying drawings:

[0037] The experimental methods used in the examples of the present invention are conventional methods unless otherwise specified. The reagents and materials used in the examples can be purchased conventionally, and the quantitative experiments involved in the examples are repeated at least three times, and the results are averaged.

[0038] The C57 / BL6 mice used were purchased from the Model Animal Center of Nanjing University.

[0039] The caerulein used was purchased from MCE Company with the product number HY-A0190.

[0040] The cholecystokinin (CCK) used was purchased from Sigma-Aldrich with the catalog number T6515.

[0041] The taurocholate sodium (TLCS) used was purchased from MCE Company with the product number HY-137255.

[0042] The chenodeoxycholic acid (CDCA) used was purchased from MCE Company with the product number HY-76847.

[0043] Example 1: Application of intraperitoneal injection of chenodeoxycholic acid (CDCA) in the prevention / treatment of acute pancreatitis I. Acute pancreatitis model induced by caerulein in mice

[0044] Experimental animals: 6-8 week old male C57BL / 6J mice (weight 20-25 g).

[0045] The experimental animals were divided into a normal control group and a cerulein model group. The model group mice were intraperitoneally injected with cerulein (100ug / kg, 1h interval, 10 injections continuously) to establish an acute pancreatitis model. The control group mice were given a strict PBS control intraperitoneal injection.

[0046] 2. Intraperitoneal injection of chenodeoxycholic acid (CDCA)

[0047] Mice in the caerulein model group were randomly divided into AP (Caerulein) group and CDCA (2.5mg / kg, 5mg / kg, 10mg / kg, 20mg / kg, 40mg / kg) treatment group, with 6 mice in each group. CDCA (dissolved in 10% DMSO solution) was intraperitoneally injected 3h after caerulein modeling, and the AP group was given the same 10% DMSO solvent for strict control. All mice were anesthetized by intraperitoneal injection of sodium pentobarbital 12h after the first intraperitoneal injection of caerulein, and the mouse serum was collected for serum enzyme levels. Subsequently, the mice underwent in vivo cardiac perfusion to remove the circulating blood, and the pancreatic tissue was quickly extracted for fixation and dehydration, and HE-stained paraffin sections and immunohistochemical staining were made.

[0048] The results are as follows Figure 1 and Figure 2 As shown, it can be seen that different concentrations of CDCA can significantly improve pancreatic tissue damage (edema, inflammatory exudation and acinar cell necrosis), improve serum enzymology and serum amylase levels, among which 40 mg / kg CDCA has the best effect. The above results suggest that intraperitoneal injection of CDCA may improve or alleviate the occurrence and development of acute pancreatitis. * represents a significant difference P < 0.05, ** represents a significant difference P < 0.01, and *** represents a significant difference P < 0.001.

[0049] Example 2: Application of intraperitoneal injection of chenodeoxycholic acid (CDCA) in the prevention / treatment of severe acute pancreatitis

[0050] 1. Severe acute pancreatitis model in mice induced by retrograde injection of sodium taurocholate into the pancreatic duct

[0051] Experimental animals: 6-8 weeks old C57 / BL6 male mice (weight 20-25 g)

[0052] The experimental animals were divided into sham operation group, model group and CDCA (40 mg / kg) treatment group (10 animals in each group).

[0053] 1. The experimental animals were anesthetized by intraperitoneal injection of sodium pentobarbital (injected according to body weight, 8ul / g).

[0054] 2. All experimental animals were anesthetized and fixed on the operating table. After laparotomy in the model group, surgical forceps were used to bluntly separate and expose the bile and pancreatic ducts, clamp the upper common bile duct, and retrogradely inject 100 μL of 1% sodium taurocholate at the opening of the duodenal papilla. The abdominal cavity was closed layer by layer and the skin was sutured. The sham operation group only underwent laparotomy and laparotomy related operations, and no retrograde injection of the pancreatic duct was performed. All mice recovered for 30 minutes on a 37°C constant temperature operating table after surgery.

[0055] 2. Intraperitoneal injection of chenodeoxycholic acid (CDCA)

[0056] The treatment group was intraperitoneally injected with CDCA (dissolved in 10% DMSO solution) at 3h, the AP group was given the same 10% DMSO solvent for strict control, and the sham-operated mice were intraperitoneally injected with 10% DMSO solution. All mice were anesthetized by intraperitoneal injection of sodium pentobarbital 12h after the start of modeling, and the mouse serum was collected for serum enzyme levels. Subsequently, the mice underwent in vivo cardiac perfusion to remove the circulating blood, and the pancreatic tissue was quickly extracted for fixation and dehydration, and paraffin sections and immunohistochemical staining for HE staining were made.

[0057] The results are as follows Figure 3 As shown in Figures A and B, 40 mg / kg CDCA can significantly improve pancreatic tissue damage (pancreatic tissue edema, inflammatory exudation, and acinar cell necrosis) in mice injected with sodium taurocholate (TLCS) via retrograde pancreatic duct. Figure 4 As shown in A and B, CDCA can improve serum enzymology and serum amylase levels.

[0058] Example 3: Application of intragastric administration of chenodeoxycholic acid (CDCA) in the prevention / treatment of acute pancreatitis

[0059] 1. Ceruin-induced acute pancreatitis model in mice

[0060] Experimental animals: 6-8 week old male C57BL / 6J mice (weight 20-25 g).

[0061] The experimental animals were divided into a normal control group and a cerulein model group. The model group mice were intraperitoneally injected with cerulein (100ug / kg, 1h interval, 10 injections continuously) to establish an acute pancreatitis model. The control group mice were given a strict PBS control intraperitoneal injection.

[0062] 2. Oral administration of CDCA

[0063] Mice in the caerulein model group were randomly divided into an AP (Caerulein) group and a CDCA (40 mg / kg) treatment group, with 6 mice in each group. CDCA (dissolved in 10% DMSO solution) was administered intragastrically 3 hours after caerulein modeling, and the AP group was given the same 10% DMSO solvent for strict control. All mice were anesthetized by intraperitoneal injection of sodium pentobarbital 12 hours after the first intraperitoneal injection of caerulein, and the mouse serum was collected for serum enzyme levels. Subsequently, the mice underwent in vivo cardiac perfusion to remove the circulating blood, and the pancreatic tissue was quickly extracted for fixation and dehydration, and HE-stained paraffin sections and immunohistochemical staining were made.

[0064] The results are as follows Figure 5 and Figure 6 As shown, it can be seen that oral administration of 40 mg / kg CDCA can significantly improve pancreatic tissue damage (edema, inflammatory exudation and acinar cell necrosis), improve serum enzymology and serum amylase levels. The above results suggest that oral administration of CDCA can also improve or alleviate the occurrence and development of acute pancreatitis. * represents a significant difference P < 0.05, ** represents a significant difference P < 0.01, and *** represents a significant difference P < 0.001.

[0065] Example 4: Application of CDCA in reducing acinar cell death in vitro (CCK-induced acinar cell injury model)

[0066] Primary acinar cells: Pancreatic acinar cells were extracted from 6-8 week old C57 / BL6 male mice, inoculated in six-well plates, and stably cultured in 1M Hepes medium (containing 10% FBS) at 37 degrees Celsius in a 5% CO2 incubator. CCK was administered to establish an in vitro cell injury (6h) model.

[0067] The specific groups are as follows:

[0068] Control group: cultured for 6 hours;

[0069] CCK group: 5 μM cholecystokinin (CCK) was added to each well and cultured for 6 h;

[0070] CCK+CDCA group: 5 μM cholecystokinin (CCK) and different concentration gradient CDCA (0.1 μM, 0.25 μM, 0.5 μM, 1 μM, 2.5 μM) were added to each well and cultured for 6 hours.

[0071] The cells in each group were collected and analyzed for lactate dehydrogenase (LDH) damage.

[0072] The results are as follows Figure 7As shown, it can be seen that different concentrations of CDCA significantly alleviated the death of acinar cells induced by CCK, among which 0.5 μM CDCA had the best protective effect. * represents a significant difference P < 0.05, ** represents a significant difference P < 0.01, and *** represents a significant difference P < 0.001.

[0073] The cells in each group were collected and stained with propidium iodide (PI) to detect cell necrosis.

[0074] The results are as follows Figure 8 As shown, it can be seen that 0.5uM CDCA significantly alleviated the death of acinar cells induced by CCK, and the number of necrotic cells positively marked by PI staining was significantly reduced.

[0075] Example 5: Application of CDCA in vitro to enhance mitochondrial function of acinar cells (CCK-induced acinar cell injury model)

[0076] Primary acinar cells: Pancreatic acinar cells were extracted from 6-8 week old C57 / BL6 male mice, inoculated in six-well plates, and stably cultured in 1M Hepes medium (containing 10% FBS) at 37 degrees Celsius in a 5% CO2 incubator. CCK was administered to establish an in vitro cell injury (6h) model.

[0077] The specific groups are as follows:

[0078] Control group: cultured for 6 hours;

[0079] CCK group: 5 μM cholecystokinin (CCK) was added to each well and cultured for 6 h;

[0080] CCK+CDCA group: 5uM cholecystokinin (CCK) and different concentration gradient CDCA (0.5uM) were added to each well and cultured for 6 hours.

[0081] Cells from each group were collected and mitochondrial membrane potential JC-1 and mitochondrial reactive oxygen species MitROS fluorescence staining were performed. Fig. 9 As shown in the figure, it can be seen that 0.5 μM CDCA significantly enhanced the mitochondrial function of acinar cells induced by CCK. Fig.10 As shown, it can be seen that 0.5 μM CDCA significantly reduced the level of mitochondrial reactive oxygen species in acinar cells induced by CCK.

[0082] Example 6: Application of CDCA in reducing acinar cell death in vitro (TLCS-induced acinar cell injury model)

[0083] Primary acinar cells: Pancreatic acinar cells were extracted from 6-8 week old C57 / BL6 male mice, seeded in six-well plates, and stably cultured in 1M Hepes medium (containing 10% FBS) at 37 degrees Celsius in a 5% CO2 incubator. TLCS was administered to establish an in vitro cell injury model (6 hours).

[0084] The specific groups are as follows:

[0085] Control group: cultured for 6 hours;

[0086] TLCS group: 1 mM sodium taurocholate (TLCS) was added to each well and cultured for 6 hours;

[0087] TLCS+CDCA group: 1 mM sodium taurocholate (TLCS) and different concentration gradients of CDCA (0.5 μM) were added to each well and cultured for 6 hours.

[0088] The cells in each group were collected and analyzed for lactate dehydrogenase (LDH) damage.

[0089] The results are as follows Fig.11 As shown, it can be seen that 0.5 μM CDCA significantly alleviated TLCS-induced acinar cell death.

[0090] The above contents are only for explaining the technical idea of ​​the present invention and cannot be used to limit the protection scope of the present invention. Any changes made on the basis of the technical solution in accordance with the technical idea proposed by the present invention shall fall within the protection scope of the claims of the present invention.

Claims

1. Use of chenodeoxycholic acid in the preparation of a drug for preventing and / or treating acute pancreatitis.

2. The use according to claim 1, It is characterized in that The medicine is a medicine for improving pancreatic tissue damage.

3. The use according to claim 2, It is characterized in that The pancreatic tissue damage includes edema, inflammatory exudate and acinar cell necrosis.

4. The use according to claim 3, It is characterized in that The drug is a drug which reduces the acinar cell death induced by cholecystokinin through chenodeoxycholic acid.

5. The use according to claim 3, It is characterized in that The drug is a drug that reduces the mitochondrial reactive oxygen level of acinar cells induced by cholecystokinin through chenodeoxycholic acid.

6. The use according to claim 3, It is characterized in that The drug is a drug which reduces the acinar cell death induced by sodium taurocholate through chenodeoxycholic acid.

7. The use according to claim 1, It is characterized in that The medicine is a medicine for improving serum enzymology and serum amylase levels.

8. The use according to claim 1, It is characterized in that The drug is administered by intragastric or intraperitoneal injection.

9. Use of chenodeoxycholic acid in the preparation of a drug for preventing and / or treating severe acute pancreatitis.

10. A drug for preventing and / or treating pancreatitis, acute pancreatitis or severe acute pancreatitis, It is characterized in that The invention is prepared by adding or not adding pharmaceutically acceptable excipients to chenodeoxycholic acid.